Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Acute Myeloid Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals. Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.

Share this video  

COSTEM 2019 | Gilteritinib for FLT+ R/R AML

Giovanni Martinelli • 26 Oct 2019
COSTEM 2019
Acute Myeloid Leukemia Leukemia Gilteritinib

Giovanni Martinelli, MD, University in Bologna, Bologna, Italy, discusses the use of gilteritinib for FLT+ R/R acute myeloid leukemia (AML). This interview was recorded at the 5th International Congress on Controversies in Stem Cell Transplantation and Cellular Therapies (COSTEM) 2019, held in Berlin, Germany.

More from Giovanni Martinelli

CAR-T updates in AML and ALL 1:42
CAR-T updates in AML and ALL
Giovanni Martinelli • 7 Dec 2019
Giovanni Martinelli: exciting CAR-T research 1:01
Giovanni Martinelli: exciting CAR-T research
Giovanni Martinelli • 25 Oct 2019
Blinatumomab for R/R Ph+ AML 1:36
Blinatumomab for R/R Ph+ AML
Giovanni Martinelli • 25 Oct 2019
How will we pave the way to transplant for high risk patients? 1:12
How will we pave the way to transplant for high risk patients?
Giovanni Martinelli • 25 Oct 2019

Related Videos

The value and mission of the International Workshop on Acute Leukemias 14:36
The value and mission of the International Workshop on Acute Leukemias
Charles Craddock et al. • 21 Oct 2025
One big question with Koichi Takahashi: what AML advance could transform frontline care in 3 years? 1:30
One big question with Koichi Takahashi: what AML advance could transform frontline care in 3 years?
Koichi Takahashi • 26 Sep 2025
One big question with Naval Daver: what AML advance could transform frontline care in three years? 1:05
One big question with Naval Daver: what AML advance could transform frontline care in three years?
Naval Daver • 26 Sep 2025
One big question with Charles Craddock: what AML advance could transform frontline care in 3 years? 3:13
One big question with Charles Craddock: what AML advance could transform frontline care in 3 years?
Charles Craddock • 26 Sep 2025
The content of VJHemOnc is intended for healthcare professionals